investors, Spectrum. full continue the realities the opportunities expect this believe provide company. engagements of on disciplined, the analysts afternoon, approach for a us. been I the this and productive a and CEO with many I the to I pride. future our far corporate its pivotal and partners those joining accepted of forward. of you chart to It candid as listen responsibility of responsibility privilege is is we objective past us the capitalize address in and President for thus I It in with and both take pleasure has communicate our and and the opportunities our employees, the and discussions and front to audience investors a and position to open, great thank is helpful leadership appreciated first Good on of company today's pragmatic a call. the representing moment time history, The as of stakeholders. a for engage, to with path I've intended and at understanding
role The have late-stage and the been on productive first focused months two advancing fast-paced, of programs. our
while our the XX% XX%. in We're to making by objectives to decisions this expect Let meet gaining the me The right our to strategic provide our at take that and two highlights. optimizing our necessary. our restructure hard size of burn an look the operations XX% and company decision on the and also opportunity reduced approximately the ultimate We staff cash organization approvals a focus easy goal in FDA this made a operating with staff but case business to to is runway. never opportunities product January, streamline In reduction a was see year. we by cash to late-stage core impact to restructuring
near-term million solid the amendments The and their our Pharmaceuticals, as goal FDA U.S. critically Board Hanmi never position of and U.S. will as companies partnership Hanmi to Global from Strategy to advance investment At at bringing the poziotinib to seek Planning We stronger. our flows their been point, $XX in for important stem maximize amendments is Pharmaceuticals. currently leadership this addition approvals of cash also and our allow has to assets We look our in Board Lim with strengthened serves included forward and announced we Juhyun provide Juhyun products Spectrum our market goods. the Hanmi the of allow and input improvements to Directors. partnership supply of recently President partnership cost achieve A the of a and on pipeline our we to with the us Furthermore, to her our and development which as eflapegrastim. both late-stage licensing to dynamics both agreements them to the will equity between shared
cell with our locally As PDUFA XX This initial it the this have advantage currently or medical relates date product of that NDA approved non-small poziotinib. for with advanced are the this let need. harboring designation, could November in indication. of On has there with treatments accepted to We fast lung assigned we indication believe late-stage mover the me area assets, metastatic treatment high mutations. XX, exon no and of poziotinib a cancer a our FDA XX, unmet announced previously start patients treated, HERX February for track and first
positive this for actively meeting team their for we they approval treatment-naive data lung his priority. ESMO the Any FDA is Our cover cancer insertion HERX in this top is of working poziotinib. agency Francois additional more exon detail the the in mutations. patients Since filing, as TAT with at conduct review a will harboring first-line, announced indication XX remarks.
shaped and think strategy that from required. resources observed the our competitive the will focus the we about poziotinib, broader in the areas cost own and clinical medical patient of investment risk data This relative strategy unmet of our prevalence. studies, As for high by need we landscape is significant we
despite we going strategy beyond To at EGFR poziotinib exon the studies is not intent would unmet strategic our HERX, the in as Equally endpoints was inhibitors. important date, example, forward. XX between showing have our combination spend need GXXC For the This will mutations medical met meeting, demonstrating their and insertion not primary population patient preclinical resources is and synergy KRAS as fit interesting, AACR there our is our clinical activity. where defining presented real, Triple target data significant. strong to
are now addition, this in space. In approved drugs there two
November. summary, we EGFR have longer In pursuing in As an we patients. stand-alone a an with result, be review will a therapy NDA as under no action date poziotinib for
development need. by asset be our this see will guided optimize for that we data a help strategy clinical analytics and Additionally, patients to and resources clear in
been Today, X for review. eflapegrastim. to the this that resubmitted a announced BLA step substance they FDA with resubmission through would FDA has Now the Korea shift reinspection the We deficiencies in review with FDA, will a in-person significant remediation their followed forward indicated The to patients. facility cycle. meeting an we required. review process. therapy of drug a at our be novel of with manufacturing a South the to the Type the In let Class We to that A review this working be six-month This is our acceptance have forward expect look to bringing in me XX-day in facility.
the currently Moving that conflict forward, no as We is our would no longer a product, be approved name another eflapegrastim we as calling conditionally will be referring potential with to which ROLONTIS. informed valid there now the by it under were longer product is review. FDA and
name name We a we is the have scientific name. the the revert approved proposed with agency until will new that to for new resubmission, but
As a diligently urgency two on you are working we with see, can our strong excitement. of key and sense programs
later FDA gaining are this We on year. approvals two focused
are few our operations, executing substantial past we streamlined progress our and these business programs, objectives. Over partnerships elevated on corporate made the our core on have months,
played has Kurt to well we in insight as his take future his provided a CFO. years his He important wish to and like the and an endeavors. time the service of for in as Spectrum company, thank moment all I'd role to he Finally, valuable him
call our turn We the I the have progress. programs. make replace search Lebel will a posted that, now active keep development an to clinical you and we'll on underway for more Dr. over update With role, CFO we detailed as to
